[go: up one dir, main page]

US20110243892A1 - Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates - Google Patents

Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates Download PDF

Info

Publication number
US20110243892A1
US20110243892A1 US13/163,080 US201113163080A US2011243892A1 US 20110243892 A1 US20110243892 A1 US 20110243892A1 US 201113163080 A US201113163080 A US 201113163080A US 2011243892 A1 US2011243892 A1 US 2011243892A1
Authority
US
United States
Prior art keywords
group
conjugate
derivatives
peg
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/163,080
Inventor
Shishan Ji
Dequan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/163,080 priority Critical patent/US20110243892A1/en
Publication of US20110243892A1 publication Critical patent/US20110243892A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Definitions

  • the present invention relates to Y-shape branched hydrophilic polymer derivatives, their preparation methods, and conjugates of the derivatives and drug molecules, especially proteins and polypeptides.
  • This invention also relates to pharmaceutical compositions comprising the conjugates.
  • Natural and recombinant proteins and polypeptides have been used as medicines.
  • the products after purification and separation can be used to treat specific diseases by parenteral routes.
  • proteins When administered parenterally, however, proteins may have immunogenicity, or be relatively insoluble in water, or have short pharmacological half-lives. How to raise and keep a highly effective serum concentration in vivo is of significant importance.
  • PEG has been widely used to conjugate proteins, peptides or other therapeutic agents, in order to prolong their physiological half-lives and lower their immunogenicity and toxicity.
  • PEG and its derivatives have been widely used as carriers in the manufacture of pharmaceutical preparations of commercial drugs.
  • the methods for conjugating PEG to drug molecules has made much progress in the last 10 years and had been applied to many officially approved drugs.
  • PEG-intron® a conjugate of PEG to ⁇ -interferon, exhibits longer circulation half-life and better therapeutic effect.
  • the conjugate of PEG to paclitaxel reduces the toxicity and increases the bioactivity.
  • the metabolism of PEG is well known, and PEG is accepted as a safe drug modifier.
  • PEGylation is often applied when conjugating PEG to drugs. Namely, one or two of the terminal groups of the PEG are activated to form a proper functional group, which is reactive to at least one functional group of the drugs, and can form a stable bond with it.
  • PEG derivatives have been reported. Linear PEG propionic acid, butanoic acid and their NHS esters have been reported in U.S. Pat. No. 5,672,662. Recently a U-shape branched PEG is reported in U.S. Pat. No. 564,357.
  • two linear PEGs link to one molecule or structure through two identical functional groups, such as two amino groups or two carboxyl groups.
  • the branched PEG is derived from linear PEG and lysine, which is a kind of amino acid having two amino groups.
  • the present invention provides a new Y-shape branched hydrophilic polymer derivative, which is represented by formula I:
  • conjugates of the above polymer derivatives and drug molecules through the functional group F there is provided conjugates of the above polymer derivatives and drug molecules through the functional group F.
  • compositions comprising the above conjugates.
  • FIG. 1 shows the synthesis of Y-shape branched polyethylene glycol derivatives (1).
  • FIG. 2 shows the synthesis of Y-shape branched polyethylene glycol derivatives (2) and (7).
  • FIG. 3 shows the synthesis of Y-shape branched polyethylene glycol derivatives (5).
  • FIG. 4 shows the synthesis of Y-shape branched polyethylene glycol derivatives (6).
  • FIG. 5 shows the synthesis of conjugates of Y-shape branched polyethylene glycol derivatives (1) and drugs (through ester bonds).
  • FIG. 6 shows the synthesis of conjugates of Y-shape branched polyethylene glycol derivatives and drugs (through other bonds).
  • FIG. 7 shows the synthesis of conjugates of Y-shape branched polyethylene glycol derivatives and proteins.
  • the hydrophilic polymer is, for example, a polyethylene glycol, a polypropylene glycol, a polyvinyl alcohol, a polyacrylmorpholine or a copolymer thereof, especially preferred are a polyethylene glycol and copolymers thereof.
  • Pa and Pb may be the same or different, and can be the PEG represented by the following formula (V):
  • R is preferably H, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclohexyl or benzyl.
  • the Y-shaped branched hydrophilic polymer derivatives of the present invention are preferably prepared by attaching two linear PEG chains to an amino group of a small molecule.
  • PEG is used here as an example to illustrate the preparation of Y-shaped branched hydrophilic polymer derivatives of the present invention.
  • R is H, a C 1-12 alkyl, a cycloalkyl base or an aralkyl, and n is an integer, representing the degree of the polymerization.
  • R can be any lower alkyl group having 1-6 carbon atoms, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-pentyl, or n-hexyl.
  • R is preferably a cycloalkyl containing 3-7 carbon atoms, for example, cyclopropyl, cyclobutyl, and cyclohexyl. Among those, cyclohexyl is more preferable.
  • the typical compound is methoxy-polyethylene glycol (mPEG).
  • mPEG methoxy-polyethylene glycol
  • Other analogs and derivatives of polyethylene glycol such as polypropylene glycols, polyvinyl alcohols, and polyacrylmorpholines and the like, can also be used in the present invention.
  • PEGs they are usually measured by molecular weight. It is preferred that the molecular weight of PEG which forms the conjugates falls in the range from 300 to 60000 Daltons, which means n is about 6 to 1300. It is more preferred that n is 28, 112 and 450, respectively corresponding to molecular weight of 1325, 5000, and 20000. Because of the potential non-homogeneity of the starting
  • PEGs which are usually defined by their, molecular weights rather than the self-repeating unit n, PEGs are normally characterized with a weight average molecular weight, rather than their self-repeating units represented by n.
  • the starting PEG compounds with different molecular weights are readily synthesized using methods known in the art or they are commercially available.
  • the Y-shape PEG derivatives of the present invention can be synthesized and prepared by general methods in this field.
  • the different compounds claimed in the invention are synthesized and prepared by known methods, which can be found in the technological literatures and patents in this field.
  • This compound can be prepared by using a standard polymerization initiator, to promote the polymerization of ethylene oxide or ethylene glycol.
  • a standard method of preparation is shown below:
  • This compound can be obtained from stepwise reactions of a PEG with a compound containing an amino group.
  • the selected compound containing an amino group can be an amino acid, an amino ketone or another molecule having an amino group.
  • the standard preparation route is illustrated below. However, there are other standard methods useful for preparing this derivative that are known in this field.
  • the F terminal group plays a key role.
  • Derivatives with different terminal groups have different uses. The introduction of these functional groups determines the applicable fields and structures of these derivatives. In respect of the desired use, the following methods can be used to modify the terminal functional group:
  • aminated PEG derivatives are important in reacting with a molecule having a carboxylic acid group to yield a conjugate.
  • Carboxylation helps to improve PEG's reactivity and makes it capable of conjugating to molecules having amino or hydroxyl groups.
  • the terminal group of the resulting Y-shaped PEG will have a carboxylic group.
  • the terminal groups will have several carboxylic acid groups. This kind of structure is useful to increase the load of small natural drug molecule and achieve a slow-release effect by stepwise degradation.
  • active functional groups such as amino, carboxyl and hydroxyl groups, which bind with monosaccharides, polysaccharides, nucleosides, polynucleosides, phosphoryl and the like in vivo, to form active pharmacological structures.
  • the PEG derivatives with the modified terminal functional group can conjugate to the drug molecules in the same way to take the place of a bio-organic molecule and overcome the shortcomings of short physiological half-lives and low therapeutic effect.
  • the following model is a general ester synthesis reaction.
  • An ester group can be eliminated by biodegradation in vivo to release the active ingredient.
  • An amide group is relatively stable in vivo.
  • the Y-shape hydrophilic polymer derivatives of the present invention can form conjugates with drug molecules through proper functional groups. These functional groups can link the free amino, hydroxyl or thiol group of proteins, polypeptides and other natural drugs with the polymer derivatives. For proteins and peptides with high molecular weight, one molecule can link with one or more PEG derivatives to improve the physiological effects of the drug molecules in vivo. For the active components of a natural drug with low molecular weight, one PEG derivative can be linked to one or more drug molecules through proper functional groups to ensure a proper drug concentration and the function of sustained release.
  • the drug molecules included in the conjugates of the present invention are the active ingredients separated from nature plants, such as paclitaxel, camptothecin, cinobufagin, clycyrrhetinic acid and scopoletin.
  • the drugs are the ingredients of natural medicines used in the treatment of tumors, such as paclitaxel, camptothecin, and derivatives thereof.
  • Preferred drugs also include interferons, such as ⁇ - and ⁇ -interferon.
  • the conjugates of the present invention can be administered in the form of pure compounds or suitable pharmaceutical compositions, via any acceptable routes or being included in a reagent for similar use.
  • the conjugates can be administered via oral, nasal, parenteral, topical, transdermal, rectal or injection routes in the form of solid, semisolid, lyophilized powder or liquid, for example, tablets, suppositories, pills, soft and hard gelatin capsules, powder, solution, suspention and aerosols.
  • the unit dosage form is suitable for a precise-dosage and easy administration.
  • the composition includes conventional pharmaceutical carriers or excipients and the conjugate(s) of the present invention as the active ingredient(s). Furthermore, it also can include other agents, carriers and excipients.
  • the pharmaceutically acceptable compositions will include about 1-99 wt. % of the conjugate of the present invention, and 99-1 wt. % of suitable pharmaceutical excipient. Preferably they include 5-75 wt. % of the conjugate and the rest is any suitable pharmaceutical excipient.
  • the pharmaceutical composition of the present invention can further include an adjuvant in a small amount, such as wetting agent, emulsifier, pH buffer, antioxidant and the like.
  • an adjuvant such as wetting agent, emulsifier, pH buffer, antioxidant and the like.
  • citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene and the like can be added.
  • composition applied will include an effective amount of the conjugate of the present invention for the treatment of corresponding disease.
  • the synthesis is shown in FIG. 1 .
  • 10 ml of dry ethylene oxide was added to a heavy-duty flask, which included 200 mg of N,N-di-2-hydroxylethyl-2-benzyloxyethyl amine and 50 mg of dry NaH.
  • the reaction mixture was stirred with the temperature being slowly increased. After 28 hours, the viscous liquid was quenched with water and the polymer was extracted with dichloromethane. The organic phase was dried with anhydrous sodium sulfate, and the solvent was removed under vacuum. Yield: 8.2 g (81%), Mp: 56-58° C.
  • the synthesis is shown in FIG. 2 .
  • 1 g of Y-shape branched PEG derivative of Mw 10000 ((MeO-PEG) 2 -N—CH 2 CH 2 OH, from example 1) and 0.1 g of di-succinimidyl carbonate were dissolved in 20 ml of acetonitrile.
  • 0.1 ml of pyridine was added to the solution.
  • the reaction mixture was stirred under the protection of nitrogen overnight.
  • the solvent was removed by rotary evaporation and the residue was dried under vacuum.
  • the solid residue was added to 10 ml of dry dichloromethane. The undissolved solid was filtered.
  • Y-shape branched mPEG acid 0.5 g was dissolved in 10 ml dichloromethane. 7 mg of N-hydroxylsuccinimide (NHS) and 13 mg of dicyclohexylcarbodiimide (DCC) was added to the solution. The solution was stirred at room temperature for 6 hours. The solvent was removed under vacuum. The residue was added to 20 ml of isopropyl alcohol (EPA). The product was collected by filtration and dried under vacuum.
  • NHS N-hydroxylsuccinimide
  • DCC dicyclohexylcarbodiimide
  • the synthesis is shown in FIG. 7 .
  • 75 mg Y-shape branched polyethylene glycol succinimidyl ester (from example 2, 5 or 6) was dissolved in 5 ml of buffered ⁇ -interferon solution with interferon concentration 5 mg/ml (pH 7.4).
  • PEG and ⁇ -interferon were at ratio of 3:1.
  • the solution was gently shaken for 1 hour at 4° C. and then 5 hours at room temperature.
  • the solution was diluted to a final interferon concentration of 0.5 mg/ml and purified by HPLC with gel column.
  • the mono-substituted Y-shape branched PEG conjugate of ⁇ -interferon was collected. SDS-PAGE showed the product contained no free ⁇ -interferon.
  • Y-shape branched polyethylene glycol succinimidyl ester (Example 5 or 6) was dissolved in 5 ml of buffered ⁇ -interferon solution with interferon concentration of 1 mg/ml (pH 7.4). In the reaction solution, PEG and ⁇ -interferon were at ratio of 3:1. The solution was gently shaken for 7 hours. The solution was purified by HPLC with gel column. The mono-substituted Y-shape branched PEG conjugate of ⁇ -interferon was collected. SDS-PAGE and CE showed the product contains no free ⁇ -interferon.
  • FIG. 5 The synthesis is shown in FIG. 5 .
  • 1 g of Y-shape branched PEG carboxylic acid (from Example 5 or 6) was dissolved in 10 ml dichloromethane.
  • 90 mg of paclitaxel, 8 mg of dimethylamino pyridine and 25 mg of dicyclohexylcarbodiimide were added to the solution.
  • the solution was stirred at room temperature for 6 hours.
  • the solvent was removed under vacuum.
  • the residue was added to 20 ml of isopropyl alcohol.
  • the precipitate was collected by filtration, washed with ether and dried under vacuum. Yield: 0.8 g (80%), Mp: 55-57° C.
  • FIG. 5 The synthesis is shown in FIG. 5 .
  • 1 g of Y-shape branched PEG carboxylic acid (Example 5 or 6) was dissolved in 20 ml of dichloromethane.
  • 30 mg of Cinobufagin, 20 mg of 1-Hydroxybenzotriazole, 20 mg of dimethylamino pyridine and 38 mg of dicyclohexyl-carbodiimide were added to the solution.
  • the solution was stirred at room temperature for 12 hours under the protection of nitrogen.
  • the solvent was concentrated under vacuum.
  • the residue was added to 20 ml of 1,4-dioxane.
  • the precipitate was collected by filtration, washed with ether and dried by air exhaust. The solvent was removed under vacuum.
  • composition comprises the conjugate of the present invention.
  • Example 8 The conjugate prepared in Example 8 was dissolved in 0.9% saline to obtain 100 ml solution for intravenous injection, which was filtered through 0.2 ⁇ m membrane and packed aseptically. The powder for injection was obtained by freeze-drying.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.

Description

    FIELDS OF THE INVENTION
  • The present invention relates to Y-shape branched hydrophilic polymer derivatives, their preparation methods, and conjugates of the derivatives and drug molecules, especially proteins and polypeptides. This invention also relates to pharmaceutical compositions comprising the conjugates.
    • BACKGROUND OF THE INVENTION
  • Natural and recombinant proteins and polypeptides have been used as medicines. The products after purification and separation can be used to treat specific diseases by parenteral routes. When administered parenterally, however, proteins may have immunogenicity, or be relatively insoluble in water, or have short pharmacological half-lives. How to raise and keep a highly effective serum concentration in vivo is of significant importance.
  • In addition to proteins, clinically there is necessity to modify other constituents of natural medicine such as flavonoids, terpenoids, anthraquinones, steroids and alkaloids to prolong their physiological half-lives, enhance their stability and the possibility to reach the target site, raise their solubility in water, change administration routes and improve bioavailability.
  • Recently PEG has been widely used to conjugate proteins, peptides or other therapeutic agents, in order to prolong their physiological half-lives and lower their immunogenicity and toxicity. Clinically, PEG and its derivatives have been widely used as carriers in the manufacture of pharmaceutical preparations of commercial drugs. The methods for conjugating PEG to drug molecules has made much progress in the last 10 years and had been applied to many officially approved drugs. For example, PEG-intron®, a conjugate of PEG to α-interferon, exhibits longer circulation half-life and better therapeutic effect. The conjugate of PEG to paclitaxel reduces the toxicity and increases the bioactivity. The metabolism of PEG is well known, and PEG is accepted as a safe drug modifier.
  • One process called PEGylation is often applied when conjugating PEG to drugs. Namely, one or two of the terminal groups of the PEG are activated to form a proper functional group, which is reactive to at least one functional group of the drugs, and can form a stable bond with it.
  • Many PEG derivatives have been reported. Linear PEG propionic acid, butanoic acid and their NHS esters have been reported in U.S. Pat. No. 5,672,662. Recently a U-shape branched PEG is reported in U.S. Pat. No. 564,357. In these PEG derivatives, two linear PEGs link to one molecule or structure through two identical functional groups, such as two amino groups or two carboxyl groups. In one example of the patent, the branched PEG is derived from linear PEG and lysine, which is a kind of amino acid having two amino groups.
    • SUMMARY OF THE INVENTION
  • The present invention provides a new Y-shape branched hydrophilic polymer derivative, which is represented by formula I:
  • Figure US20110243892A1-20111006-C00001
  • wherein
    • Pa and Pb are hydrophilic polymers, which are the same or different;
    • j is an integer from 1 to 12;
    • Ri is selected from the group consisting of H, a C1-12 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl;
    • X1 and X2 independently are linking groups, wherein X1 is (CH2)n, and X2 is selected from the group consisting of (CH2)n, (CH2)nOCO, (CH2)nNHCO and (CH2)nCO, wherein n is an integer of from 1-10; and
    • F is a functional group selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, carboxylic acid chloride, hydrazide, maleimide and pyridine disulfide, being capable of reacting with an amino group, a hydroxyl group or a thiol group of a therapeutic agent or a substrate to form a covalent linkage.
  • According to another aspect of the invention, there is provided a Y-shaped branched poly(ethylene glycol) derivatives represented by formula II:
  • Figure US20110243892A1-20111006-C00002
  • wherein
    • Pa and Pb are polyethylene glycols, which are the same or different;
    • n and j are independently an integer from 1 to 12;
    • Ri is selected from the group consisting of H, a C1-12 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl; and
    • F is a functional group selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, carboxylic acid chloride, hydrazide, maleimide and pyridine disulfide, being capable of reacting with an amino group, a hydroxyl group or a thiol group of a therapeutic agent or a substrate to form a covalent linkage.
  • According to still another aspect of the invention, there is provided a Y-shaped branched poly(ethylene glycol) derivatives represented by formula III:
  • Figure US20110243892A1-20111006-C00003
  • wherein
    • Pa and Pb are polyethylene glycols, which are the same or different;
    • n, m and j are independently an integer from 1 to 12;
    • Ri is selected from the group consisting of H, a C1-12 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl; and
    • F is a functional group selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, carboxylic acid chloride, hydrazide, maleimide and pyridine disulfide, being capable of reacting with an amino group, a hydroxyl group or a thiol group of a therapeutic agent or a substrate to form a covalent linkage.
  • According to still another aspect of the invention, there is provided a Y-shaped branched poly(ethylene glycol) derivatives represented by formula IV:
  • Figure US20110243892A1-20111006-C00004
  • wherein
    • Pa and Pb are polyethylene glycols, which are the same or different;
    • n and j are independently an integer from 1 to 12;
    • Ri is selected from the group consisting of H, a C1-12 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl; and
    • F is a functional group selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, carboxylic acid chloride, hydrazide, maleimide and pyridine disulfide, being capable of reacting with an amino group, a hydroxyl group or a thiol group of a therapeutic agent or a substrate to form a covalent linkage.
  • According to still another aspect of the invention, there is provided a method to prepare the PEG derivative of formula II, comprising:
  • at 0° C. initiating the polymerization of ethylene oxide with N,N-di-2-hydroxylethyl-2-benzyloxyethyl amine in the presence of a catalyst;
  • alkylating terminal hydroxyl groups;
  • removing benzyl groups by catalytic hydrogenation; and
  • derivatizing the new hydroxyl group to incorporate the terminal group F.
  • According to still another aspect of the invention, there is provided a method to prepare the PEG derivatives of formulae (II) and (III), comprising:
  • reacting one methoxyl polyethylene glycol mesylate with an amino acid under basic conditions,
  • reacting the product obtained above with another methoxyl polyethylene glycol derivative, and further derivatizing to incorporate a terminal group F.
  • According to still another aspect of the invention, there is provided conjugates of the above polymer derivatives and drug molecules through the functional group F.
  • According to still another aspect of the invention, there is provided pharmaceutical compositions comprising the above conjugates.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the synthesis of Y-shape branched polyethylene glycol derivatives (1).
  • FIG. 2 shows the synthesis of Y-shape branched polyethylene glycol derivatives (2) and (7).
  • FIG. 3 shows the synthesis of Y-shape branched polyethylene glycol derivatives (5).
  • FIG. 4 shows the synthesis of Y-shape branched polyethylene glycol derivatives (6).
  • FIG. 5 shows the synthesis of conjugates of Y-shape branched polyethylene glycol derivatives (1) and drugs (through ester bonds).
  • FIG. 6 shows the synthesis of conjugates of Y-shape branched polyethylene glycol derivatives and drugs (through other bonds).
  • FIG. 7 shows the synthesis of conjugates of Y-shape branched polyethylene glycol derivatives and proteins.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • In the present invention, the hydrophilic polymer is, for example, a polyethylene glycol, a polypropylene glycol, a polyvinyl alcohol, a polyacrylmorpholine or a copolymer thereof, especially preferred are a polyethylene glycol and copolymers thereof.
  • In the PEG derivatives of formulae (II) to (IV) of the present invention, Pa and Pb may be the same or different, and can be the PEG represented by the following formula (V):
  • Figure US20110243892A1-20111006-C00005
  • wherein:
    • R is H, a C1-12 allyl, cycloalkyl or aralkyl; and
    • n is an integer, representing the degree of polymerization, preferably making the molecular weight of PEG is 300 to 60000.
  • In formula (V), R is preferably H, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclohexyl or benzyl.
  • The Y-shaped branched hydrophilic polymer derivatives of the present invention are preferably prepared by attaching two linear PEG chains to an amino group of a small molecule.
  • PEG is used here as an example to illustrate the preparation of Y-shaped branched hydrophilic polymer derivatives of the present invention.
  • The general structure of PEG is as the formula below:
  • Figure US20110243892A1-20111006-C00006
  • wherein:
    R is H, a C1-12 alkyl, a cycloalkyl base or an aralkyl, and
    n is an integer, representing the degree of the polymerization.
  • As a lower alkyl, R can be any lower alkyl group having 1-6 carbon atoms, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-pentyl, or n-hexyl. As a cycloalkyl, R is preferably a cycloalkyl containing 3-7 carbon atoms, for example, cyclopropyl, cyclobutyl, and cyclohexyl. Among those, cyclohexyl is more preferable. The typical compound is methoxy-polyethylene glycol (mPEG). Other analogs and derivatives of polyethylene glycol, such as polypropylene glycols, polyvinyl alcohols, and polyacrylmorpholines and the like, can also be used in the present invention.
  • In respect of PEGs, they are usually measured by molecular weight. It is preferred that the molecular weight of PEG which forms the conjugates falls in the range from 300 to 60000 Daltons, which means n is about 6 to 1300. It is more preferred that n is 28, 112 and 450, respectively corresponding to molecular weight of 1325, 5000, and 20000. Because of the potential non-homogeneity of the starting
  • PEGs which are usually defined by their, molecular weights rather than the self-repeating unit n, PEGs are normally characterized with a weight average molecular weight, rather than their self-repeating units represented by n. The starting PEG compounds with different molecular weights are readily synthesized using methods known in the art or they are commercially available.
  • The Y-shape PEG derivatives of the present invention can be synthesized and prepared by general methods in this field. The different compounds claimed in the invention are synthesized and prepared by known methods, which can be found in the technological literatures and patents in this field.
  • For Pa and Pb being mPEGs, X1 and X2 being a simple branched alkyl, and F being a hydroxyl group, the possible formula is below:
  • Figure US20110243892A1-20111006-C00007
  • This compound can be prepared by using a standard polymerization initiator, to promote the polymerization of ethylene oxide or ethylene glycol. A standard method of preparation is shown below:
  • Figure US20110243892A1-20111006-C00008
  • For Pa and Pb being methoxy polyethylene glycols (mPEGs), X1 and X2 being different, the possible formula is below:
  • Figure US20110243892A1-20111006-C00009
  • This compound can be obtained from stepwise reactions of a PEG with a compound containing an amino group. The selected compound containing an amino group can be an amino acid, an amino ketone or another molecule having an amino group. The standard preparation route is illustrated below. However, there are other standard methods useful for preparing this derivative that are known in this field.
  • Figure US20110243892A1-20111006-C00010
  • When the hydrophilic polymer derivatives of present invention are used, the F terminal group plays a key role. Derivatives with different terminal groups have different uses. The introduction of these functional groups determines the applicable fields and structures of these derivatives. In respect of the desired use, the following methods can be used to modify the terminal functional group:
    • 1. Amination
  • Because of greater reactivity of amino groups over hydroxyl groups, the aminated PEG derivatives are important in reacting with a molecule having a carboxylic acid group to yield a conjugate.
  • Figure US20110243892A1-20111006-C00011
    • 2. Carboxylation
  • Carboxylation helps to improve PEG's reactivity and makes it capable of conjugating to molecules having amino or hydroxyl groups.
  • Figure US20110243892A1-20111006-C00012
  • If an amino acid is used as a starting material, the terminal group of the resulting Y-shaped PEG will have a carboxylic group. Especially, if multiple carboxylic acid containing amino acids or polymers are used, the terminal groups will have several carboxylic acid groups. This kind of structure is useful to increase the load of small natural drug molecule and achieve a slow-release effect by stepwise degradation.
    • 3. Other Modification Methods
  • Other modification, for example, by acid chloride, hydrazine, maleimide, pyridine disulfide and the like can be appropriately adopted as well to obtain corresponding derivatives. Other preparation methods in this field will be apparent to those skilled in this are.
  • Many components of natural drugs have active functional groups such as amino, carboxyl and hydroxyl groups, which bind with monosaccharides, polysaccharides, nucleosides, polynucleosides, phosphoryl and the like in vivo, to form active pharmacological structures.
  • Similarly, the PEG derivatives with the modified terminal functional group can conjugate to the drug molecules in the same way to take the place of a bio-organic molecule and overcome the shortcomings of short physiological half-lives and low therapeutic effect. The following model is a general ester synthesis reaction.
  • Figure US20110243892A1-20111006-C00013
  • An ester group can be eliminated by biodegradation in vivo to release the active ingredient. An amide group is relatively stable in vivo.
  • The Y-shape hydrophilic polymer derivatives of the present invention can form conjugates with drug molecules through proper functional groups. These functional groups can link the free amino, hydroxyl or thiol group of proteins, polypeptides and other natural drugs with the polymer derivatives. For proteins and peptides with high molecular weight, one molecule can link with one or more PEG derivatives to improve the physiological effects of the drug molecules in vivo. For the active components of a natural drug with low molecular weight, one PEG derivative can be linked to one or more drug molecules through proper functional groups to ensure a proper drug concentration and the function of sustained release.
  • The applications described above offer some possible reference models for medical application of the PEG derivatives. The choice of proper derivatives for real applications can be confirmed by using animal pharmacology, toxicology, clinical study and other such approaches.
  • Preferably, the drug molecules included in the conjugates of the present invention are the active ingredients separated from nature plants, such as paclitaxel, camptothecin, cinobufagin, clycyrrhetinic acid and scopoletin. Preferably, the drugs are the ingredients of natural medicines used in the treatment of tumors, such as paclitaxel, camptothecin, and derivatives thereof. Preferred drugs also include interferons, such as α- and β-interferon.
  • The conjugates of the present invention can be administered in the form of pure compounds or suitable pharmaceutical compositions, via any acceptable routes or being included in a reagent for similar use. Thus, the conjugates can be administered via oral, nasal, parenteral, topical, transdermal, rectal or injection routes in the form of solid, semisolid, lyophilized powder or liquid, for example, tablets, suppositories, pills, soft and hard gelatin capsules, powder, solution, suspention and aerosols. Preferably the unit dosage form is suitable for a precise-dosage and easy administration. The composition includes conventional pharmaceutical carriers or excipients and the conjugate(s) of the present invention as the active ingredient(s). Furthermore, it also can include other agents, carriers and excipients.
  • Generally speaking, depending on the method of administration, the pharmaceutically acceptable compositions will include about 1-99 wt. % of the conjugate of the present invention, and 99-1 wt. % of suitable pharmaceutical excipient. Preferably they include 5-75 wt. % of the conjugate and the rest is any suitable pharmaceutical excipient.
  • The preferable way of administration is injection with a general daily dosage scheme, which can be adjusted based on the severity of the disease to be treated. The conjugates of the present invention or their pharmaceutically acceptable salts may be formulated in the dosage for injection by, for example, dissolving 0.5-50% of the active components in a liquid pharmaceutical carrier, such as water, saline, aqueous glucose, glycerol, ethanol and the like to form a solution of suspension.
  • The compositions which can be administered as liquid such as solutions and suspensions can be prepared by dissolving and dispersing the conjugate of the present invention (about 0.5-20%) and optionally a the pharmaceutical excipient into a carrier. Example of carriers includes water, saline, aqueous glucose, glycerol, ethanol and the like.
  • If needed, the pharmaceutical composition of the present invention can further include an adjuvant in a small amount, such as wetting agent, emulsifier, pH buffer, antioxidant and the like. For example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene and the like can be added.
  • The practical preparation methods of such dosage forms are known or obvious to the skilled in the art. For example, see Ramington's Pharmaceutical Sciences, 18th edition, (Mack Publishing Company, Easton, Pa., 1990). In any case, according to the techniques of the present invention, the composition applied will include an effective amount of the conjugate of the present invention for the treatment of corresponding disease.
    • EXAMPLES
  • The polymer derivatives and the conjugates of the present invention and their preparation methods will be further described by the following examples. These examples do not intend to limit the scope of the invention by any means. The scope of the present invention can be determined by the claims.
    • Example 1 Synthesis of Y-Shape Branched Polyethylene Glycol Derivatives (1)
  • The synthesis is shown in FIG. 1. At 0° C., 10 ml of dry ethylene oxide was added to a heavy-duty flask, which included 200 mg of N,N-di-2-hydroxylethyl-2-benzyloxyethyl amine and 50 mg of dry NaH. The reaction mixture was stirred with the temperature being slowly increased. After 28 hours, the viscous liquid was quenched with water and the polymer was extracted with dichloromethane. The organic phase was dried with anhydrous sodium sulfate, and the solvent was removed under vacuum. Yield: 8.2 g (81%), Mp: 56-58° C.
  • 5 g of (PEG)2-N—CH2CH2O-Bz (molecular weight is 10000, obtained from above step) was dissolved in 50 ml toluene. 0.1 g of sodium hydride and 0.5 g of benzene sulfonic acid methyl ester were added to the solution. The reaction mixture was heated at 80° C. for 24 hours. Then the solution was quenched with 2 ml of isopropyl alcohol. The solvent was removed under vacuum and the residue was added to 200 ml of isopropyl alcohol. The precipitate was collected by filtration and dried in vacuum. Yield: 4.6 g (92%), Mp: 57-59° C.
  • 3 g of (MeO-PEG)2-N—CH2CH2O-Bz (molecular weight is 10000, obtained from above step) was dissolved in 30 ml of anhydrous 1,4-dioxane. Then, 0.1 g of Pd/C was added to the solution mixture as catalyst and H2 gas (40 psi) was introduced into the reactor. The solution was vigorously stirred at room temperature overnight. The catalyst was removed by filtration and was washed with fresh dichloromethane. The solvent was removed by rotary evaporation and the residue was added into ethyl ether. The precipitate was collected by filtration and dried in vacuum. Yield: 2.4 g (80%). NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 6H), 2.63 (t, 6H).
    • Example 2 Synthesis of Y-Shape Branched Polyethylene Glycol Succinimidyl Carbonate (2)
  • The synthesis is shown in FIG. 2. 1 g of Y-shape branched PEG derivative of Mw 10000 ((MeO-PEG)2-N—CH2CH2OH, from example 1) and 0.1 g of di-succinimidyl carbonate were dissolved in 20 ml of acetonitrile. 0.1 ml of pyridine was added to the solution. The reaction mixture was stirred under the protection of nitrogen overnight. The solvent was removed by rotary evaporation and the residue was dried under vacuum. The solid residue was added to 10 ml of dry dichloromethane. The undissolved solid was filtered. The organic phase was washed with sodium acetate buffer (0.1M, pH 5.5), dried with anhydrous sodium sulfate, concentrated by rotary evaporation, and precipitated in ethyl ether. The product was dried in vacuum. Yield: 0.9 g (90%). NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 6H), 4.45 (t, 2H), 2.82 (s, 4H)
    • Example 3 Synthesis of mPEG-Glycine (3)
  • 5 g mPEG of molecular weight 5000 was dissolved in 50 ml toluene, azeotropically distilled for 2 hours under the protection of nitrogen, with 10 ml solution being distilled off, and then cooled to room temperature. 3 ml of dry dichloromethane and 0.08 ml dry triethylamine were added to the reaction. The mixture was cooled in an ice-water bath and 0.12 ml of dry methanesulfonyl chloride was added dropwise. The mixture was stirred at room temperature under the protection of nitrogen overnight. The reaction was quenched by adding 2 ml of absolute ethanol. Part of the solvent was removed by rotary evaporation, the precipitate was collected by filtration, and then 150 ml ethyl ether was added. The precipitate was collected by filtration and dried in vacuum. Yield: 4.8 g (96%). NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 3H), 4.32 (t, 2H).
  • 2 g of glycine hydrochloride was dissolved in 20 ml of deionized water. 1 g of NaOH was added to the glycine solution to adjust the pH to 10.5. Then 2 g of mPEG mesylate ester of molecular weight 5000 (obtained from above step) was added to the solution. The solution was incubated at 37° C. for 72 hours, and then neutralized by hydrochloride solution to pH about 7. The polymer was extracted with dichloromethane. The organic phase was dried with anhydrous sodium sulfate and the solvent was removed under vacuum. Yield: 1.7 g (85%), Mp: 55-57° C. NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 31-1), 2.95 (t, 2H), 3.11 (s, 2H).
    • Example 4 Synthesis of mPEG-Alanine (4)
  • 5 g mPEG of molecular weight 5000 was dissolved in 50 ml of toluene, azeotropically distilled for 2 hours under the protection of nitrogen with 10 ml solvent being distilled off, and then cooled to room temperature. 3 ml of dry dichloromethane and 0.08 ml of dry triethylamine were added to the reaction. The mixture was cooled in an ice-water bath and 0.12 ml dry methanesulfonyl chloride was added dropwise. The mixture was stirred at room temperature under the protection of nitrogen overnight. The reaction was quenched by adding 2 ml of absolute ethanol. The solvent was removed by rotary evaporation, the precipitate was collected by filtration, and then 150 ml ethyl ether was added. The precipitate was collected by filtration and dried in vacuum. Yield: 4.5 g (90%). NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 3H), 4.32 (t, 2H).
  • 2 g of alanine hydrochloride was dissolved in 20 ml of deionized water. 1 g of NaOH was added to the alanine solution to adjust the pH to 10.5. Then 2 g of mPEG mesylate of molecular weight 5000 was added to the solution. The solution was incubated at 37° C. for 72 hours, and then neutralized with hydrochloride solution to pH about 7. The polymer was extracted with dichloromethane. The organic phase was dried with anhydrous sodium sulfate, and the solvent was removed under vacuum. Yield: 1.9 g (94%), Mp: 55-57° C. NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 3H), 2.94 (m, 1H), 1.24 (d, 3H).
    • Example 5 Synthesis of Y-Shape Branched PEG Derivatives (5) Reactive to an Amino Group
  • The synthesis is shown in FIG. 3. 1 g of mPEG-glycine (3) or mPEG-alanine (4) of molecular weight 5000 (from example 3 or 4) was dissolved in 20 ml of dichloromethane. 1 g of mPEG carboxyethyl NHS ester (mPEG-O—CH2—CO—NHS, molecular weight 5000) and 0.1 ml of triethylamine were added to the solution. The solution was stirred overnight. The solvent was removed under vacuum and the residue was added to ethyl ether. The precipitate was collected by filtration and dried under vacuum. The product (V-shape branched PEG acid) was further purified by ion exchange chromatography. Yield: 0.98 g (50%).
  • 0.5 g of Y-shape branched mPEG acid was dissolved in 10 ml dichloromethane. 7 mg of N-hydroxylsuccinimide (NHS) and 13 mg of dicyclohexylcarbodiimide (DCC) was added to the solution. The solution was stirred at room temperature for 6 hours. The solvent was removed under vacuum. The residue was added to 20 ml of isopropyl alcohol (EPA). The product was collected by filtration and dried under vacuum. Yield: 0.48 g (96%), NMR (DMSO): 3.5 (br m, H in PEG), 3.24, (s, 6H), 2.81 (s, 4H), 4.15 (s, 2H), 4.07 (t, 2H), 4.48 (t, 2H).
    • Example 6 Synthesis of Y-Shape Branched PEG Derivatives (6) Reactive Toward Amine Group
  • The synthesis is shown in FIG. 4. 1 g of mPEG-glycine (3) or mPEG-alanine (4) of molecular weight 5000 (from example 3 or 4) was dissolved in 20 ml of dichloromethane. 1 g of mPEG NHS carbonate (mPEGO-CO—NHS) of Mw 5000 Dalton and 0.1 ml of triethylamine were added to the solution. The solution was stirred overnight. The solvent was removed under vacuum and the residue was added to ethyl ether. The precipitate was collected by filtration and dried under vacuum. The product (Y-shape branched PEG acid) was further purified by ion exchange chromatography. Yield 0.98 g (50%)
  • 0.5 g of Y-shape branched mPEG acid was dissolved in 10 ml dichloromethane. 7 mg of N-hydroxylsuccinimide (NHS) and 13 mg of dicyclohexylcarbodiimide were added to the solution. The solution was stirred at room temperature for 6 hours. The solvent was removed under vacuum. The residue was added to 20 ml of isopropyl alcohol. The precipitate was collected by filtration and dried under vacuum. Yield 0.48 g (96%). NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 6H), 2.81 (s, 4H), 4.15 (s, 2H), 4.07 (t, 2H).
    • Example 7 Synthesis of Y-Shape Branched PEG Derivatives (7) Reactive Toward Thiol Group
  • The synthesis is shown in FIG. 2. 1 g of Y-shape branched PEG ((MeO-PEG)2-NCH2CH2OH) of molecular weight 10000 (obtained in Example 2) was dissolved in toluene, azeotropically distilled for 2 hours under protection of nitrogen, and then cooled to room temperature. 3 ml of dry dichloromethane and 0.08 ml dry triethylamine were added to the solution. The mixture was cooled in an ice-water bath and dry methanesulfonyl chloride was added dropwise. The mixture was stirred at room temperature under dry nitrogen overnight. The reaction was quenched by adding 3 ml of absolute ethanol. The solvent was removed by rotary evaporation, the precipitate was removed by filtration, and then 150 ml of ethyl ether was added. The precipitate was collected by filtration and dried in vacuum. Yield: 0.8 g (80%)
  • 1 g of Y-shape branched PEG mesylate ((MeO-PEG)2-N—CH2CH2OMs) of molecular weight 10000 was dissolved in 30 ml of aqueous ammonia solution with 5% ammonium chloride. The solution was stirred over 72 hours at room temperature. The solution was extracted with dichloromethane three times. The combined organic phase was dried with anhydrous sodium sulfate. The solvent was removed under vacuum. The residue was added to 50 ml isopropyl alcohol. The precipitate was collected and dried under vacuum. Yield: 0.7 g (70%)
  • 0.5 g of Y-shape branched PEG amine((MeO-PEG)2-N—CH2CH2NH2) was dissolved in acetonitrile. 20 mg of NHS-3-maleimidopropionate was added to the solution. The solution was stirred overnight at room temperature. The solvent was removed under vacuum. The residue was added to 30 ml isopropyl alcohol. The precipitated was collected and dried under vacuum. Yield: 0.42 g (84%). NMR (DMSO): 3.5 (br m, H in PEG), 3.24 (s, 6H), 3.05 (t, 2H), 2.56 (t, 2H), 6.71 (s, 2H in maleimide).
    • Example 8
  • Conjugate of Y-shape Branched PEG-NHS Derivatives with α-Interferon (8)
  • The synthesis is shown in FIG. 7. 75 mg Y-shape branched polyethylene glycol succinimidyl ester (from example 2, 5 or 6) was dissolved in 5 ml of buffered α-interferon solution with interferon concentration 5 mg/ml (pH 7.4). In the reaction solution PEG and α-interferon were at ratio of 3:1. The solution was gently shaken for 1 hour at 4° C. and then 5 hours at room temperature. The solution was diluted to a final interferon concentration of 0.5 mg/ml and purified by HPLC with gel column. The mono-substituted Y-shape branched PEG conjugate of α-interferon was collected. SDS-PAGE showed the product contained no free α-interferon.
  • SDS-PAGE Analysis: Reaction mixture and the purified PEG-IFN was subjected to sodium dodecyl(lauryl) sulfate/polyacrylamide (8-16%) gel electrophoresis and stained for protein using Coomassie blue dye. PEG moieties in the PEG2-IFN conjugates were specifically stained using Titrisol iodine solution (EM Science, Gibbstown, N.J.). The SDS-PAGE gel was rinsed with distilled water and placed in 5% barium chloride solution. After 10 min, the above gel was washed with distilled water and placed in 0.1 N Titrisol iodine solution for another 10 min. Titrisol was washed off with distilled water. The PEG stained (orange brown bands) SDS-PAGE gel containing Y-PEG-IFN samples was stored in distilled water in a heat-sealed Kapak/Scotchpak bag.
    • Example 9 Conjugate of Y-shape branched PEG-NHS derivatives with β-interferon
  • Y-shape branched polyethylene glycol succinimidyl ester (Example 5 or 6) was dissolved in 5 ml of buffered β-interferon solution with interferon concentration of 1 mg/ml (pH 7.4). In the reaction solution, PEG and β-interferon were at ratio of 3:1. The solution was gently shaken for 7 hours. The solution was purified by HPLC with gel column. The mono-substituted Y-shape branched PEG conjugate of β-interferon was collected. SDS-PAGE and CE showed the product contains no free β-interferon.
    • Example 10
  • Conjugate of Y-Shape Branched PEG Derivatives with Paclitaxel (10)
  • The synthesis is shown in FIG. 5. 1 g of Y-shape branched PEG carboxylic acid (from Example 5 or 6) was dissolved in 10 ml dichloromethane. 90 mg of paclitaxel, 8 mg of dimethylamino pyridine and 25 mg of dicyclohexylcarbodiimide were added to the solution. The solution was stirred at room temperature for 6 hours. The solvent was removed under vacuum. The residue was added to 20 ml of isopropyl alcohol. The precipitate was collected by filtration, washed with ether and dried under vacuum. Yield: 0.8 g (80%), Mp: 55-57° C.
    • Example 11 Conjugate of Y-Shape Branched PEG Derivatives with Camptothecin (11)
  • The synthesis is shown in FIG. 6. 1 g of Y-shape branched PEG carboxylic acid (Example 5 or 6) was dissolved in 10 ml dichloromethane. 120 mg of glycine-camptothecin, 50 mg of dimethylamino pyridine and 95 mg of dicyclohexylcarbodiimide were added to the solution. The solution was stirred at room temperature for 6 hours. The solvent was removed under vacuum. The residue was dissolved in 20 ml of 1,4-dioxane. The precipitate was removed by filtration. The solution was concentrated, and the residue was added to 20 ml of ethyl ether. The precipitate was collected by filtration, washed with ethyl ether and dried under vacuum. Yield: 0.8 g (80%), Mp: 56-58° C.
    • Example 12 Conjugate of Y-Shape Branched PEG Derivatives with Cinobufagin (12)
  • The synthesis is shown in FIG. 5. 1 g of Y-shape branched PEG carboxylic acid (Example 5 or 6) was dissolved in 10 ml dichloromethane. 60 mg of Cinobufagin, 12 mg 1-Hydroxybenzotriazole, 16 mg of dimethylamino pyridine and 40 mg of dicyclohexyl-carbodiimide were added to the solution. The solution was stirred at room temperature for 6 hours. The solvent was removed under vacuum. The residue was added to 20 ml of isopropyl alcohol. The precipitate was collected by filtration, washed with ether and dried under vacuum. Yield: 0.75 g (75%), Mp: 57-59° C.
    • Example 13
  • Conjugate of Y-Shape Branched PEG Derivatives with Scopoletin (13)
  • The synthesis is shown in FIG. 5. 1 g of Y-shape branched PEG carboxylic acid (Example 5 or 6) was dissolved in 20 ml of dichloromethane. 30 mg of Cinobufagin, 20 mg of 1-Hydroxybenzotriazole, 20 mg of dimethylamino pyridine and 38 mg of dicyclohexyl-carbodiimide were added to the solution. The solution was stirred at room temperature for 12 hours under the protection of nitrogen. The solvent was concentrated under vacuum. The residue was added to 20 ml of 1,4-dioxane. The precipitate was collected by filtration, washed with ether and dried by air exhaust. The solvent was removed under vacuum. The remaining residue was added to 100 ml of isopropyl alcohol. The precipitate was collected by filtration, washed with ether and dried by air exhaust. The precipitates were combined and dried under vacuum. Yield: 0.92 g (92%), Mp: 56-58° C.
    • Example 14 Conjugate of Y-Shape Branched PEG Derivatives with Clycyrrhetinic Acid (14)
  • The synthesis is shown in FIG. 6. 1 g of Y-shape branched PEG carboxylic acid (Example 5 or 6) was dissolved in 10 ml of dichloromethane. 0.2 ml of thionyl chloride was added to the solution. The solution was stirred for 2 hours. The solvent and impurities having low boiling point were removed under vacuum. 10 ml of dichloromethane solution having 70 mg clycyrrhetinic acid was added, and dissolved by mixing. Then 60 mg 4-dimethylamino pyridine was added. The reaction mixture was stirred for 12 hours at room temperature under the protection of nitrogen gas. The solvent was concentrated under vacuum. The residue was added into 20 ml of isopropyl alcohol. The precipitate was collected by filtration, washed with ethyl ether, dried by air exhaust, and further dried under vacuum. Yield: 0.6 g (60%). M.p.: 58˜60° C.
    • Example 15
  • This example is to illustrate the preparation process of a typical pharmaceutical composition administered parenterally. The composition comprises the conjugate of the present invention.
  • Component
    Conjugate prepared in Example 8 2 g
    0.9% saline 100 ml
  • The conjugate prepared in Example 8 was dissolved in 0.9% saline to obtain 100 ml solution for intravenous injection, which was filtered through 0.2 μm membrane and packed aseptically. The powder for injection was obtained by freeze-drying.

Claims (20)

1. (canceled)
2. The hydrophilic polymer derivative of claim 4 wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyacrylmorpholine and copolymers thereof.
3. The hydrophilic polymer derivative of claim 2 wherein the hydrophilic polymer is polyethylene glycol.
4. A Y-shaped branched hydrophilic polymer derivative represented by formula II:
Figure US20110243892A1-20111006-C00014
wherein
Pa and Pb are hydrophilic polymers, which are the same or different;
n and j are independently an integer from 1 to 12;
Ri is selected from the group consisting of H, a C1-12 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl; and
F is a functional group capable of reacting with an amino group, a hydroxyl group or a thiol group of a therapeutic agent or a substrate to form a covalent linkage, selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, carboxylic acid chloride, hydrazide, maleimide and pyridine disulfide.
5-6. (canceled)
7. The derivative of claim 4, wherein Pa and Pb are the same or different polyethylene glycols (PEGs) of formula (V):
Figure US20110243892A1-20111006-C00015
wherein
R is H, a C1-12 alkyl, a cycloalkyl or an aralkyl; and
n is an integer, representing the degree of polymerization.
8. The derivative of claim 7, wherein R is selected from the group consisting of H, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclohexyl and benzyl.
9. The derivative of claim 7, wherein the molecular weight of PEG is from about 300 to 60000.
10. A method to prepare the hydrophilic polymer derivative of claim 4, comprising:
initiating the polymerization of ethylene oxide with N,N-di-2-hydroxylethyl-2-benzyloxyethyl amine in the presence of a catalyst;
alkylating terminal hydroxyl groups; and
removing benzyl groups by catalytic hydrogenation; and
11-12. (canceled)
13. A conjugate formed by reacting the derivative of claim 4 with a drug molecule through the terminal group F.
14. (canceled)
15. The conjugate of claim 13 wherein the drug is selected from the group consisting of amino acids, proteins, enzymes, nucleosides, saccharides, organic acids, glycosides, flavonoids, anthraquinones, terpenoids, phenylpropanoid phenols, steroids, glycoside of the steroids and alkaloids of the steroids.
16. The conjugate of claim 13 wherein the drug is an active component of a natural medicine.
17. The conjugate of claim 16 wherein the active component is cinobufagin, clycyrrhetinic acid or scopoletin.
18. The conjugate of claim 13 wherein the drug is an anti-tumor agent.
19. The conjugate of claim 18 wherein the anti-tumor agent is selected from the group consisting of paclitaxel, camptothecin, interferon and derivatives thereof.
20. The conjugate of claim 19 wherein the interferon is α-, β- or γ-interferon.
21. A pharmaceutical composition comprising the conjugate of claim 13 and optionally a pharmaceutically acceptable carrier and excipient.
22. The method of claim 10, further comprising derivatizing to incorporate the terminal group F of claim 4.
US13/163,080 2002-03-13 2011-06-17 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates Abandoned US20110243892A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/163,080 US20110243892A1 (en) 2002-03-13 2011-06-17 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN0200147 2002-03-13
US10/507,452 US8003089B2 (en) 2002-03-13 2003-03-12 Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
PCT/CN2003/000179 WO2003076490A1 (en) 2002-03-13 2003-03-12 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
US13/163,080 US20110243892A1 (en) 2002-03-13 2011-06-17 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2003/000179 Division WO2003076490A1 (en) 2002-03-13 2003-03-12 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
US10/507,452 Division US8003089B2 (en) 2002-03-13 2003-03-12 Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates

Publications (1)

Publication Number Publication Date
US20110243892A1 true US20110243892A1 (en) 2011-10-06

Family

ID=27792878

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/507,452 Active 2027-11-07 US8003089B2 (en) 2002-03-13 2003-03-12 Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
US12/781,173 Abandoned US20100221213A1 (en) 2002-03-13 2010-05-17 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
US13/163,080 Abandoned US20110243892A1 (en) 2002-03-13 2011-06-17 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/507,452 Active 2027-11-07 US8003089B2 (en) 2002-03-13 2003-03-12 Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
US12/781,173 Abandoned US20100221213A1 (en) 2002-03-13 2010-05-17 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates

Country Status (9)

Country Link
US (3) US8003089B2 (en)
EP (1) EP1496076B1 (en)
JP (1) JP4272537B2 (en)
CN (1) CN1243779C (en)
AT (1) ATE368066T1 (en)
AU (1) AU2003221291A1 (en)
DE (1) DE60315145T2 (en)
ES (1) ES2291620T3 (en)
WO (1) WO2003076490A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221213A1 (en) * 2002-03-13 2010-09-02 Shishan Ji Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
US10464882B2 (en) * 2015-04-24 2019-11-05 Jenkem Technology Co., Ltd. (Beijing) Y-type discrete polyethylene glycol derivative and preparation method thereof
CN112898561A (en) * 2021-01-27 2021-06-04 大连理工大学 Maleimide-terminated polyphenylene ether and preparation method thereof

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10209822A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
MXPA05002591A (en) 2002-09-11 2005-09-20 Fresenius Kabi Gmbh Hydroxyalkyl starch derivatives.
DE10326303A1 (en) * 2003-06-11 2004-12-30 Celares Gmbh Reagents for modifying biopharmaceuticals, their manufacture and use
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
JP5191729B2 (en) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Conjugates of hydroxyalkyl starch and protein produced by reductive amination
WO2006124000A1 (en) * 2005-05-20 2006-11-23 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
US7858080B2 (en) 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
JP2009514814A (en) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション Glycosylated and glycosylated poultry-derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
EP2089052A4 (en) * 2006-05-24 2011-02-16 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
CN101168594B (en) * 2006-10-24 2011-07-27 北京键凯科技有限公司 Polyglycol active derivative with oligopeptide as framework, preparation method thereof and conjugate of with pharmaceutical molecule
CN102827284B (en) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 With the Exendin of polyethylene group or its analogue and preparation thereof and purposes
KR20100051722A (en) * 2007-08-20 2010-05-17 엔즌 파마슈티칼스, 인코포레이티드 Polymeric linkers containing pyridyl disulfide moieties
ATE548382T1 (en) * 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd POLYETHYLENE GLYCOL MODIFIED INTERFERON ALPHA 2B AND PRODUCTION METHOD AND APPLICATIONS THEREOF
CA2698396C (en) * 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
AU2007363326B2 (en) 2007-12-29 2014-01-30 Biosteed Gene Expression Tech. Co., Ltd. Y-type polyethylene glycol modified G-CSF and preparation method and use thereof
KR101521674B1 (en) * 2008-04-03 2015-05-19 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
CN101701068B (en) * 2009-10-30 2011-09-21 北京化工大学 A pH-responsive Y-shaped drug delivery material and its preparation method
JP2011105792A (en) * 2009-11-12 2011-06-02 Japan Science & Technology Agency Block copolymer, block copolymer-metal complex composite material, and hollow structure carrier using the same
FR2953720B1 (en) * 2009-12-11 2012-05-11 Oreal USE OF BENZYLOXY ETHYLAMINE DERIVATIVES AS A CONSERVATIVE,
US20140073779A9 (en) 2010-07-09 2014-03-13 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
WO2012004008A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
WO2012004009A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
EP2590680A1 (en) 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
US20140057970A1 (en) 2010-10-29 2014-02-27 Frank Schwobel Use of Hepcidin Binding Nucleic Acids for Depletion of Hepcidin From the Body
CN103083680B (en) * 2011-11-07 2014-12-24 北京键凯科技有限公司 Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition
US9327034B2 (en) 2011-12-14 2016-05-03 University Of Tsukuba, A Japanese National University Branched polyethylene glycol and use thereof
WO2014114262A1 (en) * 2013-01-28 2014-07-31 天津键凯科技有限公司 Water soluble polymer-amino acid oligopeptide-medicine combination, preparation method therefore, and use thereof
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
CN103965458B (en) * 2013-01-28 2017-02-15 天津键凯科技有限公司 Polyethylene glycol-amino acid oligopeptide-dasatinib conjugate and pharmaceutical composition thereof
CN104109235B (en) * 2014-05-30 2017-07-18 厦门赛诺邦格生物科技股份有限公司 A kind of single functionalized poly (ethylene glycol), preparation method and its bio-related substance with nitrogen-atoms branch centers
CN107446908A (en) * 2016-06-01 2017-12-08 湖南华腾制药有限公司 Polyethyleneglycol modified L L-Asparaginasums of branching type and preparation method thereof
CN106750250B (en) * 2016-12-21 2019-04-23 沈阳化工大学 Polyethylene glycol oleanolic acid derivative with amino acid as linking arm and preparation method and application thereof
CN108530637B (en) * 2017-03-05 2021-03-30 厦门赛诺邦格生物科技股份有限公司 Preparation method of single-functionalized branched polyethylene glycol
CN108659227B (en) * 2017-03-30 2020-11-06 北京键凯科技股份有限公司 Preparation method of Y-type branched hydrophilic polymer carboxylic acid derivative
WO2018177055A1 (en) * 2017-03-30 2018-10-04 北京键凯科技股份有限公司 Method for preparing y-branched hydrophilic polymer carboxylic acid derivative
CN108530642B (en) * 2017-11-24 2021-01-15 四川大学 Biodegradable triblock hetero-arm star-shaped amphiphilic polymer material and preparation method thereof
CN109400868B (en) * 2018-11-30 2021-01-15 吉林化工学院 Synthesis method of polyethylene glycol mono-anisole compound
WO2022047243A1 (en) 2020-08-27 2022-03-03 Enosi Life Sciences Corp. Methods and compositions to treat autoimmune diseases and cancer
US20250235540A1 (en) 2022-04-12 2025-07-24 Xiamen Sinopeg Biotech Co., Ltd. Non-linear pegylated lipid and application thereof
CN117510828A (en) 2022-07-28 2024-02-06 厦门赛诺邦格生物科技股份有限公司 Tri-arm polyethylene glycol derivative containing amino acid residue
EP4656202A1 (en) 2023-02-09 2025-12-03 Xie, Yanhui Treatment of atopic dermatitis with polyethylene glycol-modified interleukin 2, glucocorticoid and hyaluronic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978098A (en) * 1972-04-15 1976-08-31 Snia Viscosa Societa Nazionale Industria Applicazioni Viscosa S.P.A. Method and additives for imparting antistatic properties to polyamide compositions and polyamides obtained according to said method and with the use of said additives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756285A (en) * 1969-09-17 1971-03-17 Hoechst Ag FLUORINE POLYOXETHYLATION PRODUCTS THAT CAN BE USED FOR TEXTILE APPRETATION
GB1361627A (en) * 1970-08-04 1974-07-30 Marumo H Detergent composition
US4520145A (en) * 1982-07-21 1985-05-28 The Boots Company Plc Modified thermosetting imide resins with improved fracture toughness
DE3730797A1 (en) 1987-09-14 1989-03-23 Siegel Rolf Materials having a non-thrombogenic surface
GB2215806B (en) 1988-02-15 1992-02-05 Hakko Co Method of applying a lining to a pipeline
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH0362814A (en) * 1989-07-29 1991-03-18 Nisshinbo Ind Inc Hydrophilic polycarbodiimide polymer, pulp-like substance from the same and its production
JP2902201B2 (en) 1991-03-18 1999-06-07 ストックハウゼン ルイジアナ リミティド Method for reducing residual acrylic acid content of superabsorbent polymer
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1997001631A1 (en) 1995-06-26 1997-01-16 Daiichi Pure Chemicals Co., Ltd. Stable plasmin solution
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
PL189698B1 (en) * 1996-03-12 2005-09-30 Pg Txl Co Water-soluble promedicines of paklitaxel
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
CN1164533A (en) 1997-01-09 1997-11-12 云南汉德技术发展有限公司 Water-soluble anticancer compound-polyamino acid toxol ester
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CA2399022A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
CN1125097C (en) 2000-07-05 2003-10-22 天津大学 Precursor of polyglycol carried taxusol or polyene taxusol
CN100475269C (en) * 2002-03-05 2009-04-08 北京键凯科技有限公司 Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use thereof
EP1496076B1 (en) 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
CN1309763C (en) 2002-10-31 2007-04-11 日本化药株式会社 High-molecular weight derivatives of camptothecins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978098A (en) * 1972-04-15 1976-08-31 Snia Viscosa Societa Nazionale Industria Applicazioni Viscosa S.P.A. Method and additives for imparting antistatic properties to polyamide compositions and polyamides obtained according to said method and with the use of said additives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221213A1 (en) * 2002-03-13 2010-09-02 Shishan Ji Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
US10464882B2 (en) * 2015-04-24 2019-11-05 Jenkem Technology Co., Ltd. (Beijing) Y-type discrete polyethylene glycol derivative and preparation method thereof
CN112898561A (en) * 2021-01-27 2021-06-04 大连理工大学 Maleimide-terminated polyphenylene ether and preparation method thereof

Also Published As

Publication number Publication date
JP4272537B2 (en) 2009-06-03
US8003089B2 (en) 2011-08-23
ES2291620T3 (en) 2008-03-01
CN1243779C (en) 2006-03-01
AU2003221291A1 (en) 2003-09-22
US20050180946A1 (en) 2005-08-18
EP1496076B1 (en) 2007-07-25
JP2005520006A (en) 2005-07-07
CN1556828A (en) 2004-12-22
US20100221213A1 (en) 2010-09-02
EP1496076A1 (en) 2005-01-12
WO2003076490A1 (en) 2003-09-18
ATE368066T1 (en) 2007-08-15
DE60315145T2 (en) 2008-04-30
WO2003076490A8 (en) 2004-10-28
DE60315145D1 (en) 2007-09-06
EP1496076A4 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
US8003089B2 (en) Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
EP1489125B1 (en) Compound of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicines
JP6030717B2 (en) Polyalkylene glycols having moieties for the binding of biologically active compounds
CN103755949B (en) Multi-arm polyethylene glycol derivative and with the binding substances of medicine and gel
US11208530B2 (en) Multi-arm polyethylene glycol, preparation method and uses thereof
JP6790133B2 (en) Multi-arm polyethylene glycol and its active derivatives
WO2005121181A1 (en) Multi-drop tree branching polyethylene glycol-oligopeptides and active derivates and pharmaceutical compounds there of
WO2005092898A1 (en) The conjugates of a hydrophilic polymer-tripterygium's extracts and the pharmaceutical compositions thereof
US20050033058A1 (en) Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
US20050220753A1 (en) Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them
CN101306203B (en) Combination of hydrophilic polymer-boxwood extract and its pharmaceutical composition
US7708978B2 (en) Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders
CN111346234A (en) Deferoxamine-eight-arm star-shaped polyethylene glycol conjugate and application thereof
KR100888371B1 (en) Antiviral agent including branched polymer derivative and interferon conjugate
US20220298302A1 (en) Siloxy polyethylene glycol and derivatives thereof
KR100761652B1 (en) Various polymer derivatives and conjugates that bind to proteins or peptides
CN1556801A (en) Hydrophilic polymer-flavone conjugate and pharmaceutical composition comprising the conjugate

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION